{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009236","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.518267+00:00","generated_at":"2026-06-17T21:17:58.171448+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tempest Therapeutics FY2022 net loss $35.7M; cash $31.2M; TPST-1120 HCC data H1 2023","bullets":["Cash and equivalents $31.2M as of Dec 31, 2022, down from $51.8M; runway to Q2 2024.","Net loss $35.7M vs $28.3M in 2021; R&D expenses $22.5M (+31% YoY).","TPST-1120 Phase 1 showed 30% ORR at highest doses in checkpoint-inhibitor non-responsive patients.","Randomized Phase 1b/2 study in first-line HCC fully enrolled; initial data expected H1 2023.","TPST-1495 Phase 1 dose escalation ongoing; initial data expected by mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009236","json":"https://secwatch.observer/filing/0000950170-23-009236.json","markdown":"https://secwatch.observer/filing/0000950170-23-009236.md","text":"https://secwatch.observer/filing/0000950170-23-009236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023009236/0000950170-23-009236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023009236/tpst-20230322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:17:58.171448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d5eb9136d8389a024a8f29771494865d2315b72c","claim":"Tempest Therapeutics, Inc. reported the year ended December 31, 2022 results: net income $35.7 million, EPS $3.09.","evidence_excerpt":"Net loss and net loss per share for the year were $35.7 million and $3.09, respectively, compared to $28.3 million and $7.47, respectively, for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023009236/0000950170-23-009236-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$35.7 million"},{"label":"EPS","value":"$3.09"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}